CRESCENT BIOPHARMA, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
CRESCENT BIOPHARMA, INC. (CBIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $198.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $101.00K, a 339.13% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $97.00K.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $95.00K.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $94.00K, a 59.24% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $212.00K, a 47.35% decline from fiscal 2024.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $402.65K, a 52.97% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $856.24K, a 3.79% increase from fiscal 2022.
- CRESCENT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $825.01K, a 10.14% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 0 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $198.00K 10-Q · filed 2026-07-30 | $293.00K derived: sum of 3 quarters · filed 2026-07-30 | $387.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $97.00K 10-Q · filed 2026-04-29 | $192.00K derived: sum of 2 quarters · filed 2026-04-29 | $286.00K derived: sum of 3 quarters · filed 2026-04-29 | $309.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $189.00K derived: sum of 2 quarters · filed 2026-02-26 | $212.00K derived: sum of 3 quarters · filed 2026-07-30 | $212.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $117.00K derived: sum of 2 quarters · filed 2026-07-30 | $117.00K 10-Q · filed 2025-11-06 | $117.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $23.00K 10-Q · filed 2026-07-30 | $23.00K derived: sum of 3 quarters · filed 2026-07-30 | $82.03K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-04-29 | $59.03K derived: sum of 3 quarters · filed 2026-04-29 | $233.08K derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | $59.03K derived: sum of 2 quarters · filed 2026-02-26 | $233.08K derived: sum of 3 quarters · filed 2026-02-26 | $402.65K 10-K · filed 2025-02-13 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $59.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $233.08K derived: sum of 2 quarters · filed 2024-11-13 | $402.65K 10-Q · filed 2024-11-13 | $590.13K derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $174.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $343.62K 10-Q · filed 2024-08-08 | $531.10K derived: sum of 3 quarters · filed 2025-05-14 | $758.29K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-03-31 | $169.57K 10-Q · filed 2025-05-14 | $357.05K derived: sum of 2 quarters · filed 2025-05-14 | $584.24K derived: sum of 3 quarters · filed 2025-05-14 | $806.69K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $187.48K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $414.67K derived: sum of 2 quarters · filed 2025-02-13 | $637.12K derived: sum of 3 quarters · filed 2025-02-13 | $856.24K 10-K · filed 2025-02-13 | |
| 2023-09-30 | $227.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $449.64K derived: sum of 2 quarters · filed 2024-11-13 | $668.76K 10-Q · filed 2024-11-13 | $882.60K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $222.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $441.57K 10-Q · filed 2024-08-08 | $655.41K derived: sum of 3 quarters · filed 2024-08-08 | $864.10K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $219.12K 10-Q · filed 2024-05-09 | $432.97K derived: sum of 2 quarters · filed 2024-05-09 | $641.65K derived: sum of 3 quarters · filed 2024-05-09 | $845.32K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $213.85K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $422.53K derived: sum of 2 quarters · filed 2024-03-27 | $626.20K derived: sum of 3 quarters · filed 2024-03-27 | $825.01K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $208.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $412.35K derived: sum of 2 quarters · filed 2023-11-03 | $611.16K 10-Q · filed 2023-11-03 | $805.24K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-06-30 | $203.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $402.48K 10-Q · filed 2023-08-02 | $596.56K derived: sum of 3 quarters · filed 2024-03-27 | $786.00K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2022-03-31 | $198.81K 10-Q · filed 2023-05-03 | $392.89K derived: sum of 2 quarters · filed 2024-03-27 | $582.33K derived: sum of 3 quarters · filed 2024-03-27 | $767.27K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2021-12-31 | $194.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $383.52K derived: sum of 2 quarters · filed 2024-03-27 | $568.45K derived: sum of 3 quarters · filed 2024-03-27 | $749.04K 10-K · filed 2024-03-27 | |
| 2021-09-30 | $189.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $374.38K derived: sum of 2 quarters · filed 2022-11-09 | $554.96K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $184.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $365.52K 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | $180.59K 10-Q · filed 2022-04-28 | ||||
| 2020-12-31 | $680.85K 10-K · filed 2023-03-29 | ||||
| 2019-12-31 | $620.07K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |